Colorectal Cancer

Early-stage detection of colorectal cancer (CRC) could be achieved using a noninvasive multiomics liquid biopsy test, according to a recent study.

The new guidelines are another method of keeping a high-quality standard for colorectal cancer screening.

Cancer detection was slower to rebound after the COVID-19 pandemic compared with endoscopic activity, specifically in gastric cancers such as colorectal cancer.

Many patients could be at risk of colorectal cancer (CRC) without realizing as most patients don’t know if their immediate family has had CRC.

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted with patients.

Patients with symptoms of gastrointestinal (GI) problems and survivors of colon cancer were more likely to use oncology specialty care.

A simple, user-friendly decision-making model that used self-reported information was able to perform well in outpatient decision-making for patients with colorectal cancer (CRC).

Patients with colorectal liver metastases had local tumor progression when they had minimal ablative margin from intraprocedural contrast-enhanced computed tomography.

Tumor location, tumor size, and T stage associated with patients with rectal cancer who have inferior mesenteric artery lymph node metastases.

The Shield blood test developed by Guardant has been approved by the FDA as a primary screening option for colorectal cancer, providing a more convenient method of screening.

Patients diagnoesd with metabolic dysfunction–associated steatotic liver disease may have a higher risk of colorectal cancer (CRC) or colorectal adenoma.

Overall and site-specific colorectal cancer (CRC) had a negative association with the usage of aspirin.

A nomogram model that included log odd of positive lymph node was effective in predicting prognosis of early-onset colorectal cancer (EOCRC).

Between 2016 and 2021, the percentage of screening colonoscopies performed by a family physician saw a decrease across the country.

In a recent study, novel genetic associations between obesity, colorectal cancer (CRC), and irritable bowel disease (IBD) were identified.

Patients who used adjuvant chemotherapy were found to have a higher survival rate after achieving complete pathological response.

Adult patients who have KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) can use adagrasib as a supplemental treatment.

Both preoperative pan-immune inflammation value (PIV) and monocyte to high-density lipoprotein ratio (MHR) were found to be independent risk factors when it came to the prognosis for colorectal cancer (CRC).

Older adults who had colorectal surgery were found to have reduced postoperative complications if they started the Geriatric Oncology Service.

A recent review found that benzene exposure due to work may be linked to the development of colorectal cancer.

A dose escalation strategy for regorafenib could improve the cost-effectiveness of the medication in metastatic colorectal cancer (CRC).

The Hospital Frailty Risk Score, Secondary Care Administrative Records Frailty index, and the frailty syndromes measures were able to assess frailty in patients diagnosed with colorectal cancer (CRC).

Clinical use of liquid biopsies to determine the likelihood of CRC is the goal based on its effectiveness in recent studies.

MicroRNAs could be a key to future testing for colorectal cancer (CRC) and determining treatment.

Ajay Goel, PhD, AGAF, discusses study findings that could help in earlier detection of lymph node metastases and colorectal cancer (CRC).